New drug combo aims to keep mantle cell lymphoma in check

NCT ID NCT02896582

Completed Disease control Sponsor: The Lymphoma Academic Research Organisation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested whether adding the targeted drug obinutuzumab to standard chemotherapy (DHAP) and stem cell transplant could better control mantle cell lymphoma in 86 previously untreated patients. Participants received obinutuzumab during induction, before transplant, and as maintenance for up to 3 years. The main goal was to see if the cancer could be cleared at a molecular level in the bone marrow after initial treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Obinutuzumab (a targeted antibody drug) given with chemotherapy (DHAP, BEAM) and followed by stem cell transplant and maintenance therapy.
What this could lead to: If successful, this approach could improve long-term control of mantle cell lymphoma and reduce the chance of the cancer coming back.
What could go wrong: This is a small, early-phase trial (86 people) with no comparison group, so results may not apply broadly. The treatment involves strong chemotherapy and transplant, which carry serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

APHP - Hopital Necker

Paris, 75743, France
CH Perpignan

Perpignan, 66046, France
CH d'Avignon

Avignon, 84902, France
CHD Vendée

La Roche-sur-Yon, 85925, France
CHRU Bretonneau

Tours, 37044, France
CHRU Lille - Hôpital Claude Huriez

Lille, 59037, France
CHU Limoges

Limoges, 87042, France
CHU Lyon Sud

Pierre-Bénite, 69130, France
CHU Montpellier

Montpellier, 34295, France
CHU Nantes

Nantes, 44093, France
CHU Pontchaillou

Rennes, 35033, France
CHU Robert Debré

Reims, 51092, France
CHU d'Amiens

Amiens, 80480, France
CHU d'Angers

Angers, 49000, France
CHU de Brabois

Vandœuvre-lès-Nancy, France
CHU de Caen

Caen, 14033, France
CHU de Clermont Ferrand

Clermont-Ferrand, 63000, France
CHU de Dijon - Hôpital le Bocage

Dijon, 21034, France
CHU de Grenoble

Grenoble, 38700, France
CHU de Haut Leveque

Pessac, 33604, France
CHU de Poitiers

Poitiers, 86021, France
CHU de Strasbourg

Strasbourg, 67091, France
Centre Henri Becquerel

Rouen, 76038, France
Centre Hospitalier Annecy-Genevois

Pringy, 74374, France
Clinique Victor Hugo

Le Mans, 72000, France
Gustave Roussy Cancer Campus

Villejuif, 94805, France
Hopital Henri Mondor

Créteil, 94010, France
Hôpital Saint Louis

Paris, 75475, France
I.U.C.T Oncopole

Toulouse, 31100, France
Institut de Cancérologie de Loire

Saint-Priest-en-Jarez, 42271, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.